Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Yes, you can still donate “source plasma” after being vaccinated.
Four hemophilia organizations issue a joint statement saying patients can get the COVID-19 vaccine and offering guidance on h…
Amid a continuing pandemic, here’s how we’re honoring the legacy of Martin Luther King Jr. in 2021.
Because of COVID-19, for the first time, the microbe emoji soared in popularity and in March featured in one out of every 50…
Based on its creator’s real-life kidney transplant, the CBS show aims for laughs and to raise awareness.
A recent survey shed light on how this rare disease affects daily life and what they value most.
On our podcast, CSL’s Chief Digital Information Officer - and Army veteran - Mark Hill discusses how technology will continue…
A world-class facility for 500 researchers is set to open in Marburg in the second half of 2022.
Alpha 1 patients send heartfelt thanks to plasma donors and those who make life-saving, plasma-derived medicines.
Americas
Asia Pacific
Middle East
Europe
